Nuveen Asset Management LLC Reduces Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Nuveen Asset Management LLC cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 304,115 shares of the company's stock after selling 7,740 shares during the period. Nuveen Asset Management LLC owned about 1.06% of Krystal Biotech worth $47,643,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in KRYS. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares during the period. Avanza Fonder AB bought a new position in shares of Krystal Biotech in the fourth quarter worth about $119,000. KBC Group NV increased its holdings in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after purchasing an additional 433 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on KRYS shares. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup reduced their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, May 16th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $211.13.

Krystal Biotech Stock Performance

Krystal Biotech stock traded down $0.24 during mid-day trading on Friday, reaching $125.05. 298,645 shares of the company were exchanged, compared to its average volume of 308,069. The business has a fifty day moving average of $161.34 and a 200 day moving average of $166.79. The firm has a market cap of $3.61 billion, a P/E ratio of 41.82 and a beta of 0.79. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).